Vallon Pharmaceuticals, Inc. (VLON)


-0.06 (-13.04%)
Symbol VLON
Price $0.4
Beta -1.149
Volume Avg. 8.09M
Market Cap 5.393M
Shares () -
52 Week Range 0.2054-16.5
1y Target Est -
DCF Unlevered VLON DCF ->
DCF Levered VLON LDCF ->
ROE -219.04% Strong Sell
ROA -169.17% Strong Sell
Operating Margin -
Debt / Equity 77.28% Buy
P/E -0.03 Neutral
P/B 1.73 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest VLON news

Mr. David C. Baker
NASDAQ Capital Market

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.